Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

ABSTRACT:

Objective

To establish evidence-based recommendations for the molecular analysis of lung cancers that are required to guide EGFR- and ALK-directed therapies, addressing which patients and samples should be tested, and when and how testing should be performed.

Participants

Three cochairs without conflicts of interest were selected, one from each of the 3 sponsoring professional societies: College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Writing and advisory panels were constituted from additional experts from these societies.

Evidence

Three unbiased literature searches of electronic databases were performed to capture articles published from January 2004 through February 2012, yielding 15

SUBMITTER: Lindeman NI 

PROVIDER: S-EPMC4162344 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature